Peptide Library

A Novo Nordisk investigational co-agonist targeting GLP-1 and amylin pathways, now closely watched as a next-wave obesity candidate.

A long-acting amylin analogue often discussed alongside GLP-1 therapies in obesity-drug development.

A Novo Nordisk investigational combination of cagrilintide and semaglutide, designed to pair amylin and GLP-1 pathways in obesity.

A selective amylin receptor agonist from Eli Lilly that has moved into Phase 3 obesity trials.

A GLP-1 and glucagon dual agonist developed with Innovent and Lilly, notable for obesity data and approval progress in China.

A balanced GLP-1 and glucagon dual agonist from Altimmune with obesity and liver-disease relevance.

A long-acting amylin analog from Zealand Pharma being developed for obesity and overweight.

A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors, showing unprecedented 24.2% weight loss in clinical trials. Expected FDA approval in 2027.

A GLP-1 receptor agonist used in FDA-approved products for type 2 diabetes, chronic weight management, and additional labeled uses depending on brand and indication.

An investigational dual-agonist obesity and metabolic-disease candidate that shows up in next-wave incretin discussions.

A dual GIP and GLP-1 receptor agonist used in FDA-approved products for type 2 diabetes and chronic weight management.

A peptidomimetic that targets prohibitin on the vasculature of white adipose tissue, inducing apoptosis of fat cells and rapid weight loss in primate models.

A modified fragment of human growth hormone discussed in weight-management and fat-metabolism circles, but not approved as an FDA drug.

The native 31-amino-acid active form of human glucagon-like peptide-1, cleaved from proglucagon in intestinal L cells, whose one-to-two-minute half-life under DPP-4 is the reason every marketed GLP-1 drug is an analog rather than the hormone itself.

A mitochondria-associated peptide frequently discussed in longevity circles for cytoprotective and metabolic-interest pathways.

An acylated 31-amino-acid analog of human GLP-1 dosed once daily by subcutaneous injection, approved for type 2 diabetes in 2010 and for chronic weight management in 2014 as the first GLP-1 receptor agonist licensed for obesity.

A mitochondria-derived peptide studied in metabolic and exercise-related aging discussions.

A gut hormone that acts on GLP-1 and glucagon-related pathways and helped shape the modern obesity-peptide conversation.

A satiety-linked gut hormone that has long been studied in obesity and appetite regulation.

A synthetic 37-amino-acid analog of human amylin, stabilized by three proline substitutions, approved in 2005 as a mealtime adjunct to insulin in type 1 and type 2 diabetes and discontinued by its manufacturer in 2025.

An orally dosed nitroalkene derivative of salicylate — not a peptide — reported to raise energy expenditure by activating creatine-dependent thermogenesis in adipose tissue, with one completed Phase 1 trial and no marketing authorization anywhere.

An orally dosed nitroalkene derivative of salicylate — not a peptide — reported to raise energy expenditure by activating creatine-dependent thermogenesis in adipose tissue, with one completed Phase 1 trial and no marketing authorization anywhere.

An FDA-approved MC4R agonist marketed as Imcivree for specific rare genetic forms of obesity.

A myostatin-linked muscle-growth name that remains popular in research-market and performance discussions despite limited conventional therapeutic development.

A 15-amino acid peptide derived from human gastric juice, extensively studied for tissue regeneration, gut healing, and injury recovery across multiple systems.

A GHRH analog commonly discussed in growth-hormone optimization circles and research-market peptide stacks.

A growth hormone secretagogue that appears in older GH-optimization discussions and research-market listings.

A classic growth hormone secretagogue that remains common in peptide-market catalogs despite limited mainstream clinical relevance.

Recombinant 191-amino-acid human growth hormone, sequence-identical to the main 22 kDa pituitary isoform and FDA-approved for growth hormone deficiency and related conditions since the 1980s — and, unlike the secretagogues it is routinely confused with, governed by a federal distribution felony statute of its own.

The native 70-amino-acid growth factor that carries out much of growth hormone's action; its recombinant form, mecasermin, is FDA-approved for severe primary IGF-1 deficiency, while the research market mostly sells engineered analogs instead.

A truncated IGF-1 analog that remains a familiar name in performance and tissue-growth peptide discussions.

A long-acting insulin-like growth factor analog discussed in physique and performance communities rather than approved peptide medicine.

A 67-amino-acid growth factor encoded by the imprinted IGF2 gene, central to fetal development and held in check by a dedicated clearance receptor, with no approved product anywhere and no human trials of its administration.

A ghrelin-mimetic growth hormone secretagogue often paired with CJC-1295 in research-market discussions.

The recombinant N-terminal prodomain of GDF-8 that binds mature myostatin and holds it in a latent, inactive complex; it enlarges muscle in mice but has never been given to humans in a registered trial.

A pegylated mechano growth factor analogue often discussed in performance and recovery circles.

A GHRH analogue with older clinical and diagnostic history that now appears frequently in the research and wellness peptide market.

A small-molecule ERRα/γ agonist studied as an exercise mimetic, shown to increase oxidative muscle fiber composition and endurance capacity in preclinical models.

A synthetic small molecule — not a peptide — that activates all three estrogen-related receptors and, unlike its predecessor SLU-PP-332, is orally bioavailable, studied in mice as an exercise mimetic with no published human data.

A synthetic version of the active region of thymosin beta-4, commonly discussed for soft-tissue recovery and injury support.

A growth hormone-releasing hormone analog approved in the United States for reducing excess abdominal fat in certain adults with HIV-associated lipodystrophy.

The acetylated N-terminal tetrapeptide of thymosin beta-4, degraded almost exclusively by ACE and studied in animals as an antifibrotic and anti-inflammatory signal, with the only human studies of the administered peptide run in the 1990s as a chemotherapy myeloprotectant.

A copper-binding tripeptide (Ala-His-Lys-Cu) studied for hair follicle stimulation and wound healing, structurally related to GHK-Cu but with a different amino acid sequence.

An endogenous seven-amino-acid peptide of the renin-angiotensin system that activates the MAS receptor and counteracts angiotensin II, developed clinically as TXA127 and tested for two decades across oncology, COVID-19, and muscle-wasting indications without an approval anywhere or a replicated efficacy result.

An erythropoietin-derived peptide fragment studied for tissue-protective and neuropathy-related applications without the red-blood-cell effects of full EPO.

A 15-amino acid peptide derived from human gastric juice, extensively studied for tissue regeneration, gut healing, and injury recovery across multiple systems.

A synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator family, studied for cartilage-protective and geroprotective effects in preclinical models.

A synthetic hexapeptide analog of Leu-enkephalin (Tyr-D-Ala-Gly-Phe-Leu-Arg) registered as an injectable anti-ulcer and pancreatitis drug in Russia, acting as a peripherally restricted opioid agonist that does not meaningfully cross the blood-brain barrier.

The native 53-amino-acid human growth factor that drives epithelial cell proliferation through the EGF receptor, marketed outside the United States as an intralesional diabetic foot ulcer treatment and used in cosmetics as sh-Oligopeptide-1.

A 155-amino-acid human growth factor that activates every FGF receptor in a heparin-dependent manner, studied in angiogenesis, wound-healing, and nerve-repair trials that never reached approval and sold almost exclusively as a laboratory reagent.

A copper-binding peptide used in cosmetic and wound-healing discussions, especially around skin appearance and tissue signaling.

A tripeptide antioxidant composed of glutamate, cysteine, and glycine, central to cellular detoxification, immune function, and oxidative stress defense.

The native human growth factor FGF-7, secreted by fibroblasts to drive epithelial repair through the FGFR2b receptor; its N-truncated recombinant form palifermin is FDA approved for severe oral mucositis, while KGF-1 itself remains a research reagent.

A short peptide fragment associated with gut-barrier, inflammatory, and tissue-soothing discussions in the peptide market.

A synthetic eight-amino-acid peptide derived from a Vibrio cholerae toxin fragment, developed as an oral zonulin antagonist and tight-junction regulator for celiac disease, whose Phase 3 trial was stopped after a failed interim analysis in 2022.

Nicotinamide adenine dinucleotide, a coenzyme central to cellular energy metabolism and DNA repair, studied for age-related decline and its role in sirtuin activation.

A two-chain peptide hormone of the insulin superfamily that signals through the RXFP1 receptor to produce vasodilation and antifibrotic effects, and whose recombinant form, serelaxin, failed the RELAX-AHF-2 phase 3 trial in acute heart failure.

An orally dosed polypeptide complex extracted from the cartilage and bone tissue of young animals, part of the natural branch of the Khavinson bioregulator line, studied almost entirely in Russian-language cell, animal, and uncontrolled clinical work.

A mitochondria-targeted peptide studied for cellular energy and tissue-protection questions.

A synthetic version of the active region of thymosin beta-4, commonly discussed for soft-tissue recovery and injury support.

The seven-amino-acid actin-binding segment of thymosin beta-4 (residues 17-23, LKKTETQ), sold on the research market in N-acetylated form as a smaller synthetic stand-in for the full 43-amino-acid parent peptide.

A recombinant 33-amino-acid analog of glucagon-like peptide-2, engineered for DPP-4 resistance and FDA-approved in 2012 as Gattex, that reduces parenteral-support dependence in short bowel syndrome by expanding the gut's absorptive capacity.

An endogenous dipeptide of beta-alanine and L-histidine, concentrated in skeletal muscle and brain, studied for pH buffering, anti-glycation, and carbonyl scavenging; oral doses are rapidly degraded by the serum enzyme carnosinase.

An oral capsule preparation of bovine pineal peptide extract from the Khavinson bioregulator program, marketed as the A-8 counterpart to injectable Epithalamin and distinct from the synthetic tetrapeptide epitalon.

A short peptide associated with longevity and telomere-oriented anti-aging discussion in the research market.

A tripeptide antioxidant composed of glutamate, cysteine, and glycine, central to cellular detoxification, immune function, and oxidative stress defense.

Recombinant 191-amino-acid human growth hormone, sequence-identical to the main 22 kDa pituitary isoform and FDA-approved for growth hormone deficiency and related conditions since the 1980s — and, unlike the secretagogues it is routinely confused with, governed by a federal distribution felony statute of its own.

A mitochondria-associated peptide frequently discussed in longevity circles for cytoprotective and metabolic-interest pathways.

A large (~130 kDa) glycosylated transmembrane and circulating protein encoded by the KL gene, known for mouse lifespan genetics and a single-dose rhesus macaque cognition study, with no human trial of the protein itself.

Lipotec's (now Lubrizol's) trade name for pentapeptide-18 (H-Tyr-D-Ala-Gly-Phe-Leu-OH), a metabolically stabilized leu-enkephalin analog sold as a topical cosmetic ingredient and studied for softening expression lines by damping neurotransmitter release at the neuromuscular junction.

Sederma's trade name for palmitoyl pentapeptide-4 (pal-KTTKS), a fatty-acid-conjugated fragment of type I procollagen used in topical cosmetic formulations and studied for collagen-signaling and wrinkle-reduction effects in skin.

A mitochondria-derived peptide studied in metabolic and exercise-related aging discussions.

A synthetic lipopeptide pairing the collagen-derived matrikine GHK with a palmitic-acid chain for skin penetration, used in topical cosmetics and best known as the collagen-signaling half of the Matrixyl 3000 blend.

Sederma's trade name for palmitoyl tetrapeptide-7 (Pal-GQPR, CAS 221227-05-0), a palmitoylated fragment of human immunoglobulin G used in topical cosmetics for reported IL-6-modulating, skin-soothing effects and best known as half of the Matrixyl 3000 blend.

An orally dosed polypeptide complex extracted from the cartilage and bone tissue of young animals, part of the natural branch of the Khavinson bioregulator line, studied almost entirely in Russian-language cell, animal, and uncontrolled clinical work.

A mitochondria-targeted peptide studied for cellular energy and tissue-protection questions.

A synthetic cosmetic peptidomimetic (INCI: dipeptide diaminobutyroyl benzylamide diacetate) designed to imitate waglerin-1 from temple viper venom, marketed for topical expression-line smoothing on a manufacturer-described mechanism of reversible antagonism at the muscle nicotinic acetylcholine receptor.

A copper-binding tripeptide (Ala-His-Lys-Cu) studied for hair follicle stimulation and wound healing, structurally related to GHK-Cu but with a different amino acid sequence.

Native 13-amino-acid melanocortin hormone cleaved from proopiomelanocortin that activates MC1R, MC3R, MC4R, and MC5R, driving pigmentation, appetite suppression, and anti-inflammatory signaling; it is the parent molecule of melanotan I, melanotan II, and KPV.

The native 53-amino-acid human growth factor that drives epithelial cell proliferation through the EGF receptor, marketed outside the United States as an intralesional diabetic foot ulcer treatment and used in cosmetics as sh-Oligopeptide-1.

A copper-binding peptide used in cosmetic and wound-healing discussions, especially around skin appearance and tissue signaling.

The native human growth factor FGF-7, secreted by fibroblasts to drive epithelial repair through the FGFR2b receptor; its N-truncated recombinant form palifermin is FDA approved for severe oral mucositis, while KGF-1 itself remains a research reagent.

A short peptide fragment associated with gut-barrier, inflammatory, and tissue-soothing discussions in the peptide market.

Lipotec's (now Lubrizol's) trade name for pentapeptide-18 (H-Tyr-D-Ala-Gly-Phe-Leu-OH), a metabolically stabilized leu-enkephalin analog sold as a topical cosmetic ingredient and studied for softening expression lines by damping neurotransmitter release at the neuromuscular junction.

Sederma's trade name for palmitoyl pentapeptide-4 (pal-KTTKS), a fatty-acid-conjugated fragment of type I procollagen used in topical cosmetic formulations and studied for collagen-signaling and wrinkle-reduction effects in skin.

A melanocortin peptide analogue tied to pigmentation and photoprotection research, and closely related to the approved drug afamelanotide.

A melanocortin analogue commonly discussed for tanning and cosmetic interest but not approved as an FDA drug.

A synthetic lipopeptide pairing the collagen-derived matrikine GHK with a palmitic-acid chain for skin penetration, used in topical cosmetics and best known as the collagen-signaling half of the Matrixyl 3000 blend.

A melanocortin peptide best known in regulated medicine as bremelanotide and in the research market as PT-141.

A synthetic fusion peptide pairing a cell-penetrating protein transduction domain with the Dishevelled-binding motif of CXXC5, studied topically in mice for hair regrowth and wound healing via Wnt/beta-catenin pathway activation.

Sederma's trade name for palmitoyl tetrapeptide-7 (Pal-GQPR, CAS 221227-05-0), a palmitoylated fragment of human immunoglobulin G used in topical cosmetics for reported IL-6-modulating, skin-soothing effects and best known as half of the Matrixyl 3000 blend.

A cosmetic-facing peptide often discussed in topical anti-wrinkle and expression-line products.

A synthetic cosmetic peptidomimetic (INCI: dipeptide diaminobutyroyl benzylamide diacetate) designed to imitate waglerin-1 from temple viper venom, marketed for topical expression-line smoothing on a manufacturer-described mechanism of reversible antagonism at the muscle nicotinic acetylcholine receptor.

A GHRH analog commonly discussed in growth-hormone optimization circles and research-market peptide stacks.

A growth hormone secretagogue that appears in older GH-optimization discussions and research-market listings.

A classic growth hormone secretagogue that remains common in peptide-market catalogs despite limited mainstream clinical relevance.

A growth hormone secretagogue and ghrelin-receptor agonist that remains a familiar legacy name in GH-peptide stacks.

Recombinant 191-amino-acid human growth hormone, sequence-identical to the main 22 kDa pituitary isoform and FDA-approved for growth hormone deficiency and related conditions since the 1980s — and, unlike the secretagogues it is routinely confused with, governed by a federal distribution felony statute of its own.

The native 70-amino-acid growth factor that carries out much of growth hormone's action; its recombinant form, mecasermin, is FDA-approved for severe primary IGF-1 deficiency, while the research market mostly sells engineered analogs instead.

A truncated IGF-1 analog that remains a familiar name in performance and tissue-growth peptide discussions.

A long-acting insulin-like growth factor analog discussed in physique and performance communities rather than approved peptide medicine.

A 67-amino-acid growth factor encoded by the imprinted IGF2 gene, central to fetal development and held in check by a dedicated clearance receptor, with no approved product anywhere and no human trials of its administration.

A ghrelin-mimetic growth hormone secretagogue often paired with CJC-1295 in research-market discussions.

A pegylated mechano growth factor analogue often discussed in performance and recovery circles.

A GHRH analogue with older clinical and diagnostic history that now appears frequently in the research and wellness peptide market.

A growth hormone-releasing hormone analog approved in the United States for reducing excess abdominal fat in certain adults with HIV-associated lipodystrophy.

A high-curiosity neurotrophic research peptide discussed for cognition and synaptogenesis, but still lacking real clinical development.

A peptide complex extracted from calf cerebral cortex and sold as oral capsules in the Khavinson bioregulator line, distinct from the defined synthetic bioregulator peptides and without any published study naming the product itself.

A Russian prescription injectable made from a water-soluble polypeptide fraction of cattle or pig cerebral cortex, marketed for stroke and encephalopathy — an undefined tissue extract rather than a single peptide, never reviewed by the FDA.

A synthetic eight-amino-acid fragment (NAPVSIPQ) of activity-dependent neuroprotective protein, developed as an intranasal microtubule-stabilizing tau therapy, whose 313-patient phase 2/3 trial in progressive supranuclear palsy was negative on every endpoint.

A peptide discussed for sleep-related and neuroregulatory interest, though its evidence base is far less concrete than vendor listings suggest.

A synthetic hexapeptide (Thr-Gly-Glu-Asn-His-Arg) corresponding to residues 41–46 of human leukemia differentiation factor, studied almost entirely by one Russian research network — in rodent models of neurodegeneration and, on a separate track, as a tumor-cell differentiating agent — with no human trial anywhere.

A free-acid N-acetylated analog of the Russian anxiolytic peptide Selank, capped at the N-terminus while retaining the native C-terminal carboxyl, sold in the research market with no published studies of its own.

A free-acid N-acetylated analog of Semax, the Russian intranasal nootropic, capped at the N-terminus while retaining the native C-terminal carboxyl; the capped peptide itself has just two published papers, both chemistry-led, and no clinical record.

An N-acetylated, amidated form of Semax designed for enhanced stability, studied for nootropic and neuroprotective effects via BDNF upregulation and melanocortin receptor activity.

An orally active dipeptide-derived small molecule — INN omberacetam — registered as a prescription nootropic in Russia and sold on the Western research market with no randomized or placebo-controlled human trial, no registered clinical study, and no FDA approval.

A synthetic peptide associated with anxiolytic and cognitive-interest discussions in nootropic communities.

A synthetic neuropeptide analog often discussed for cognitive and neuroprotection-related interest in research-market circles.

A hypothalamic tripeptide (pGlu-His-Pro-NH2) that triggers pituitary TSH and prolactin release; its two U.S. diagnostic injections are both discontinued, and its neuropsychiatric research record is a long series of rapid but transient effects.

A neuropeptide related to somatostatin that has been studied for anti-inflammatory, neuroendocrine, and cardiovascular effects.

A short peptide fragment associated with gut-barrier, inflammatory, and tissue-soothing discussions in the peptide market.

A synthetic eight-amino-acid peptide derived from a Vibrio cholerae toxin fragment, developed as an oral zonulin antagonist and tight-junction regulator for celiac disease, whose Phase 3 trial was stopped after a failed interim analysis in 2022.

A host-defense peptide associated with innate immunity and tissue-response discussions.

An endogenous opioid pentapeptide (Tyr-Gly-Gly-Phe-Met), also called Opioid Growth Factor, studied as a tonic inhibitor of cell proliferation through a non-classical receptor; its small human trials in cancer and autoimmune disease were open-label or terminated, and the one industry development program was abandoned over pharmacokinetics.

A free-acid N-acetylated analog of the Russian anxiolytic peptide Selank, capped at the N-terminus while retaining the native C-terminal carboxyl, sold in the research market with no published studies of its own.

An N-acetylated, amidated form of Selank designed for enhanced stability and nasal bioavailability, studied for anxiolytic and nootropic effects via tuftsin-related immune modulation.

Sederma's trade name for palmitoyl tetrapeptide-7 (Pal-GQPR, CAS 221227-05-0), a palmitoylated fragment of human immunoglobulin G used in topical cosmetics for reported IL-6-modulating, skin-soothing effects and best known as half of the Matrixyl 3000 blend.

A synthetic peptide associated with anxiolytic and cognitive-interest discussions in nootropic communities.

A synthetic neuropeptide analog often discussed for cognitive and neuroprotection-related interest in research-market circles.

A splenic polypeptide identified in the 1980s as a near-twin of thymopoietin, differing at a single active-site residue; its bovine sequence runs 49 residues, while the human 48-residue sequence paper was later retracted.

A synthetic dipeptide (Glu-Trp) from the Khavinson bioregulator family, studied for thymic bioregulation and immune system support in aging.

A thymus-derived peptide complex often discussed in immune and longevity circles.

An immune-oriented peptide discussed for immunomodulatory signaling and clinical research in infectious disease and oncology-adjacent contexts.

A synthetic dipeptide (Lys-Glu) from the Khavinson bioregulator family, studied for thymic and immune system bioregulation and geroprotective effects.

A vasoactive intestinal peptide associated with neuroimmune and inflammatory signaling discussions.

An oral preparation of low-molecular-weight peptides extracted from calf thymus, designated A-6 in the Khavinson bioregulator line, marketed for immune support on the strength of injectable thymus-extract literature rather than any study of the product itself.

A Novo Nordisk investigational co-agonist targeting GLP-1 and amylin pathways, now closely watched as a next-wave obesity candidate.

A Lilly investigational peptide candidate being studied in alcohol use disorder, mood disorders, and other craving-linked conditions.

A Novo Nordisk investigational combination of cagrilintide and semaglutide, designed to pair amylin and GLP-1 pathways in obesity.

A selective amylin receptor agonist from Eli Lilly that has moved into Phase 3 obesity trials.

A GLP-1 and glucagon dual agonist developed with Innovent and Lilly, notable for obesity data and approval progress in China.

A balanced GLP-1 and glucagon dual agonist from Altimmune with obesity and liver-disease relevance.

A long-acting amylin analog from Zealand Pharma being developed for obesity and overweight.

Native 13-amino-acid melanocortin hormone cleaved from proopiomelanocortin that activates MC1R, MC3R, MC4R, and MC5R, driving pigmentation, appetite suppression, and anti-inflammatory signaling; it is the parent molecule of melanotan I, melanotan II, and KPV.

An endogenous peptide ligand for the APJ receptor with cardiovascular and metabolic research relevance.

A GLP-1 receptor antagonist, also known as exendin 9-39, now in Phase 3 for post-bariatric hypoglycemia.

A synthetic decapeptide GnRH receptor antagonist — EU-authorised in 1999 and FDA-approved in 2000 — used to prevent premature LH surges during controlled ovarian stimulation, suppressing gonadotropins by competitive receptor blockade instead of the flare-then-downregulation route GnRH agonists take.

A neuropeptide related to somatostatin that has been studied for anti-inflammatory, neuroendocrine, and cardiovascular effects.

A glucagon analog approved in the United States as Zegalogue for severe hypoglycemia.

A synthetic V2-selective analog of vasopressin, FDA approved since 1978, that concentrates urine through renal aquaporin-2 trafficking and raises von Willebrand factor and factor VIII without the pressor activity of the parent hormone.

The pituitary gonadotropin that drives ovarian follicle maturation and Sertoli cell function, licensed in the United States as recombinant follitropin alfa and follitropin beta and as urine-derived menotropins for fertility indications.

The 28-amino-acid stomach hormone that is the natural ligand for the GHS-R1a growth hormone secretagogue receptor, requiring an octanoyl group on serine 3 for activity — the modification that makes it chemically fragile and clinically impractical.

The native 31-amino-acid active form of human glucagon-like peptide-1, cleaved from proglucagon in intestinal L cells, whose one-to-two-minute half-life under DPP-4 is the reason every marketed GLP-1 drug is an analog rather than the hormone itself.

A GnRH analogue tied to endocrine signaling, diagnostic history, and fertility-related peptide discussions.

A dimeric glycoprotein hormone that activates the LH/hCG receptor to drive gonadal steroidogenesis, licensed as an injectable prescription biologic for cryptorchidism, male hypogonadotropic hypogonadism, and ovulation induction.

A growth hormone secretagogue and ghrelin-receptor agonist that remains a familiar legacy name in GH-peptide stacks.

A two-chain, 51-amino-acid protein hormone secreted by pancreatic beta cells and the first peptide drug ever given to a patient, in 1922; dozens of recombinant human and analog products now hold FDA approval for diabetes.

A reproductive-axis signaling peptide studied for its role in GnRH release and fertility-related endocrinology.

The 54-residue kisspeptin isoform, also called metastin, that activates the KISS1R receptor to drive hypothalamic GnRH release; it is the form used in most human reproductive-endocrinology trials, including IVF oocyte-maturation triggering.

A long-acting somatostatin analog marketed as Somatuline Depot and used in neuroendocrine and acromegaly-related care.

A synthetic nonapeptide GnRH superagonist that initially stimulates and then durably suppresses gonadotropin secretion, FDA-approved since 1985 in daily and long-acting depot formulations for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.

The anterior-pituitary gonadotropin that triggers ovulation and drives Leydig-cell testosterone production; its recombinant form, lutropin alfa (Luveris), was approved in the U.S. in 2004 but had that approval withdrawn in 2016, leaving hCG as the clinical LH-activity surrogate.

A melanocortin peptide analogue tied to pigmentation and photoprotection research, and closely related to the approved drug afamelanotide.

A melanocortin analogue commonly discussed for tanning and cosmetic interest but not approved as an FDA drug.

An FDA-approved leptin analog used in rare metabolic disease, best known in the United States as Myalept.

A somatostatin analog widely used in endocrine and neuroendocrine medicine, and one of the most important approved peptide drugs missing from many peptide libraries.

A gut hormone that acts on GLP-1 and glucagon-related pathways and helped shape the modern obesity-peptide conversation.

A peptide hormone used in FDA-approved medical settings but also frequently reframed in wellness and research-market discussions.

An FDA-approved somatostatin analog marketed as Signifor, used in Cushing's disease and related endocrine settings.

A satiety-linked gut hormone that has long been studied in obesity and appetite regulation.

A melanocortin peptide best known in regulated medicine as bremelanotide and in the research market as PT-141.

A two-chain peptide hormone of the insulin superfamily that signals through the RXFP1 receptor to produce vasodilation and antifibrotic effects, and whose recombinant form, serelaxin, failed the RELAX-AHF-2 phase 3 trial in acute heart failure.

An FDA-approved MC4R agonist marketed as Imcivree for specific rare genetic forms of obesity.

A splenic polypeptide identified in the 1980s as a near-twin of thymopoietin, differing at a single active-site residue; its bovine sequence runs 49 residues, while the human 48-residue sequence paper was later retracted.

A peptide-complex extract from animal testicular tissue, sold as oral capsules within the Khavinson bioregulator line and marketed for male reproductive support, with no published sequence, no identified target, and no compound-specific human trials.

A hypothalamic tripeptide (pGlu-His-Pro-NH2) that triggers pituitary TSH and prolactin release; its two U.S. diagnostic injections are both discontinued, and its neuropsychiatric research record is a long series of rapid but transient effects.

A cyclic nonapeptide hormone, also called antidiuretic hormone, that controls renal water reabsorption and vascular tone through V1a, V1b, and V2 receptors and is FDA approved as an intravenous vasopressor.

An FDA-approved C-type natriuretic peptide analog marketed as Voxzogo for achondroplasia.

A Lilly investigational peptide candidate being studied in alcohol use disorder, mood disorders, and other craving-linked conditions.

A high-curiosity neurotrophic research peptide discussed for cognition and synaptogenesis, but still lacking real clinical development.

A myostatin-linked muscle-growth name that remains popular in research-market and performance discussions despite limited conventional therapeutic development.

A small-molecule NNMT inhibitor studied for its potential to increase cellular energy expenditure and reduce fat accumulation by blocking nicotinamide N-methyltransferase.

An endogenous peptide ligand for the APJ receptor with cardiovascular and metabolic research relevance.

A GLP-1 receptor antagonist, also known as exendin 9-39, now in Phase 3 for post-bariatric hypoglycemia.

A 37-amino-acid sensory neuropeptide and one of the most potent vasodilators described in humans; every FDA-approved drug in this space blocks CGRP rather than supplying it, and the peptide itself has no approved product.

A neuropeptide related to somatostatin that has been studied for anti-inflammatory, neuroendocrine, and cardiovascular effects.

A synthetic hexapeptide analog of Leu-enkephalin (Tyr-D-Ala-Gly-Phe-Leu-Arg) registered as an injectable anti-ulcer and pancreatitis drug in Russia, acting as a peripherally restricted opioid agonist that does not meaningfully cross the blood-brain barrier.

A D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells, studied as a senolytic agent that selectively induces apoptosis in aging cells.

An endogenous opioid pentapeptide (Tyr-Gly-Gly-Phe-Leu) isolated from brain in 1975 that preferentially activates delta-opioid receptors, is degraded within minutes by peptidases, and circulates today as a laboratory reference reagent rather than a therapeutic.

A seven-amino acid fragment of the neuropeptide spadin, studied as a TREK-1 channel blocker with potential antidepressant-like effects in preclinical models.

A synthetic peptide containing an HDM2-binding domain and a membrane-penetrating sequence, studied for selective cytotoxicity against cancer cells expressing surface-bound HDM2.

A synthetic tetrapeptide (Lys-Glu-Asp-Pro) from the Khavinson bioregulator family, studied for prostatic tissue bioregulation and geroprotective effects.

A synthetic fusion peptide pairing a cell-penetrating protein transduction domain with the Dishevelled-binding motif of CXXC5, studied topically in mice for hair regrowth and wound healing via Wnt/beta-catenin pathway activation.

Injectable complex of water-soluble polypeptide fractions extracted from cattle retina, used in Russian ophthalmology for glaucoma and retinal disease; its evidence base is largely Russian-language clinical literature, with no FDA approval or registered Western trials.

An orally dosed nitroalkene derivative of salicylate — not a peptide — reported to raise energy expenditure by activating creatine-dependent thermogenesis in adipose tissue, with one completed Phase 1 trial and no marketing authorization anywhere.

An orally dosed nitroalkene derivative of salicylate — not a peptide — reported to raise energy expenditure by activating creatine-dependent thermogenesis in adipose tissue, with one completed Phase 1 trial and no marketing authorization anywhere.

A synthetic tetrapeptide (Lys-Glu-Asp-Gly) from the Khavinson bioregulator family, studied for testicular tissue bioregulation and age-related hormonal support.